Pharmacetical Newswire

Pharmaceutical News!

Press release distribution service
Pharmaceutical Links

Pharmanewswire.Com: Pharmaceutical News

Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations




(PharmaNewsWire.Com, January 10, 2017 )
GBI Research, a leading business intelligence provider, has released its latest research report,""Asthma Therapeutics in Major Developed Markets to 2020 Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations"".The Asthma Therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.

The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.

Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=275426

Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.

Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.

Scope

The report covers and includes

An introduction to asthma, including discussion of disease epidemiology, etiology pathophysiology, symptoms, diagnosis, and treatment, with clinical data for drugs featured in the current treatment algorithm discussed in detail
In-depth analysis of the current marketed products landscape, including product profiles of the main drugs used and heat maps that compare their safety and efficacy parameters
Comprehensive analysis of the asthma pipeline by phase of development, molecule type, and molecular target and novelty, and comparative analysis of the most promising late-stage pipeline drugs, as well as heat maps and a competitor matrix that compares safety and efficacy parameters
Additional in-depth analysis of the asthma clinical trials landscape, including trends in size, duration and failure rate

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at: http://mymarketresearchlifereports.blogspot.in/

Researchmoz Global Pvt.Ltd

Researchmoz

+1-518-621-2074

sales@researchmoz.us

Source: EmailWire.Com

Source: EmailWire.com


Pharmaceutical Sponsors

Free Biotech & Pharmaceutical Magazines

Pharmacy Newswire Video Feed

Pharmaceutical & Biotech Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:

IronPort Provides Email Management and Analysis for a Premier Health Care Solutions Provider
Pharmaceutical & Medical Packaging News
Medical Laboratory Observer

No credit cards, coupons, or promo codes required. Try it today!

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com, or contact us.
Copyright 2009 GroupWeb Media LLC
GroupWeb Media Network

Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | i-SoftwareNews.com | iT-NewsWire.Com
| i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net
Pharmanewswire.com - Pharmaceutical Newswire and Press Release service of GroupWeb Media LLC